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Background: Dendritic cells (DC) are uniquely equipped to capture, process, and present antigens from their
environment. The context in which an antigen is acquired by DC helps to dictate the subsequent immune
response. Cancer vaccination promotes antitumor immunity by directing an immune response to antigens
expressed by tumors. We have tested the tumor-associated antigen alpha-fetoprotein (AFP) as an immunotherapy
target. The majority of hepatocellular carcinomas (HCC) upregulate and secrete this oncofetal antigen.
Methods: To develop cancer vaccines for HCC capable of promoting potent tumor-specific T cell responses, we
tested adenovirally-encoded synthetic AFP, with or without its signal sequence, as well as protein forms of AFP and
compared intracellular routing and subsequent antigen-specific CD8+ and CD4+ T cell responses.
Results: Surprisingly, the secreted form of antigen was superior for both CD4+ and CD8+ T cell activation. We also
examined the mechanism through which AFP protein is endocytosed and trafficked in human DC. We identify the
mannose receptor (MR/CD206) as the primary uptake pathway for both normal cord blood-derived AFP (nAFP) and
tumor-derived AFP (tAFP) proteins. While in healthy donors, nAFP and tAFP were cross-presented to CD8+ T cells
similarly and CD4+ T cell responses were dependent upon MR-mediated uptake. In HCC patient cells, tAFP was
more immunogenic, and CD4+ T cell responses were not MR-dependent.
Conclusions: Secreted, cytoplasmically retained, and endocytosed forms of AFP utilize unique uptake and
processing pathways, resulting in different immunologic responses from the induced antigen-specific CD4+ and
CD8+ T cells and between healthy donors and HCC patients. Collectively, these data elucidate pathways of
spontaneous and induced anti-tumor immunity in HCC patients to this secreted antigen.
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DC play a key role in initiating the adaptive immune re-
sponse by sampling antigens from their environment
and presenting them to lymphocytes. The physiologic
cues received by DC as antigen is taken up impact pro-
cessing and presentation and help to shape subsequent
lymphocyte responses [1, 2]. DC were shown initially to* Correspondence: butterfieldl@upmc.edu
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creativecommons.org/publicdomain/zero/1.0/utilize both (macro)pinocytosis and the mannose receptor
(MR/CD206), a C-type lectin receptor (CLR), to take up
and concentrate model antigens like horseradish peroxid-
ase and mannosylated bovine serum albumin (BSA) [3].
Scavenger receptors, CLRs, heat shock proteins, and Fc
receptors are also antigen uptake mechanisms used by DC
[4]. Endocytosis of the model protein antigen ovalbumin
via scavenger receptors promotes lysosomal degradation
of ovalbumin, MHC II-restricted presentation, and activa-
tion of CD4+ T cells. In contrast, uptake via MR results in
enhanced cross-presentation of antigen to CD8+ T cellsrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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transport between endosomes and the cytosol [6]. Add-
itional studies suggest that antigen uptake by receptors that
facilitate early endosomal routing and accumulation of anti-
gen in endosomes, rather than lysosomal delivery and pro-
teolytic digestion, should promote cross-presentation,
prolonged antigen presentation and subsequently induce
superior CD8+ T cell activation, an essential component of
anti-tumor immunity [7, 8].
Alpha-fetoprotein (AFP) is the most abundant serum
protein in the fetus, reaching levels of up to 3 mg/ml in
fetal blood [9]. It is transcriptionally repressed shortly
after birth, and normal adult levels are between 1–
20 ng/ml. The reappearance of AFP in the circulation of
adults is associated with liver regeneration, hepatitis,
chronic liver diseases and malignant growth, including
hepatomas and teratomas [10]. Serum assays of circulat-
ing AFP play an important role in the diagnosis of hepa-
tocellular carcinoma (HCC) and monitoring responses
to treatment. In contrast to fetal AFP, tumor-secreted
AFP is differentially glycosylated [11, 12]. A fucosylated
variant, known as AFP-L3, is the major glycoform in
HCC patient serum and is associated with poor outcome
[13]. The uptake of AFP by multiple cell types, including
epithelial cells, activated lymphocytes and tumor cells,
has been observed [14–17], although a specific cell sur-
face receptor has not yet been definitively identified [17].
Given its common over-expression by the majority of
HCC tumors, AFP represents an attractive target for im-
munotherapy [18]. It has been demonstrated that both
CD4+ and CD8+ T cells can recognize AFP epitopes
presented by dendritic cells (DC) [19]. Our group ob-
served that CD8+ T cells from healthy donors can
respond to four dominant and ten subdominant HLA-
A*0201-restricted peptides in vitro [20]. At least three
clinical trials have tested AFP-based vaccine regimens: i)
four immunodominant HLA-A*0201-restricted AFP
peptides emulsified in Montanide adjuvant [21], ii) AFP
peptide-pulsed autologous DC [22], and iii) a DNA-
prime/adenovirus (AdV)-boost genetic immunization
[23]. Although no objective clinical responses were ob-
served in the small numbers of vaccinated patients,
AFP-specific T cell responses were either developed or
expanded in the majority of patients. The association be-
tween AFP secretion and poor clinical outcome, HCC
stemness [24] and tumor growth rate supports further
testing of AFP as an immunogenic tumor-associated
antigen target. Because of the inherent variability in hu-
man self-tumor antigen responses and the small size of
most cancer vaccine clinical trials, it is not yet clear how
to load DC with antigen optimally for CTL induction.
Clinical trials continue to utilize a wide array of antigen
sources and uptake pathways to attempt to promote
antitumor immunity. It is also increasingly clear thatthere is considerable tumor-immune crosstalk before tu-
mors become clinically evident, and many patients have
spontaneous immune responses to tumor antigens with-
out vaccination or other therapy.
In this study, we examined different forms of AFP
antigen to identify how the antigen is taken up, proc-
essed, and presented by DC. By investigating the fetal
and tumor-induced immunity to this secreted antigen
and examining the subsequent impact on T cell re-
sponses, we inform the design of future vaccination
strategies targeting this oncofetal antigen.Results and discussion
AdV-transduction induces partial maturation of DC
We have previously utilized adenoviral vectors for
genetic engineering of DC due to their ability to ex-
press full length antigens within DC and positively im-
pact some aspects of DC function [25–29]. To further
characterize the maturation effects of AdV on DC, we
first transduced healthy donor (HD) DC with an AFP-
encoding AdV (AdVhAFP) and monitored the expres-
sion of several maturation markers over the course of
3 days. Compared to immature DC (iDC) and LPS/
IFN-γ-matured DC (mDC), AdV-transduced DC
exhibited intermediate expression levels of antigen
presentation molecules (HLA-ABC, HLA-DR) and
costimulatory molecules (CD40, CD83, CD80, CD86)
(Fig. 1a). We also analyzed expression of the endocytic
receptors MR and CD36 following AdV-transduction
(Fig. 1b). Unlike mDC, which highly downregulate
these receptors, AdV-transduced DC express levels
similar to iDC, suggesting that AdV infection does not
compromise the endocytic function of DC.Adenovirally-expressed AFP localizes to the Golgi
apparatus and related compartments in DC
To determine the intracellular expression patterns of
adenovirally-expressed AFP, DC were transduced for
3 hr and AFP localization was examined by fluores-
cent microscopy for 24, 48, or 72 hr post-infection.
Throughout the observation period, the AFP trans-
gene was detected almost exclusively in the peri-
nuclear space (Fig. 2). Adenovirally-expressed AFP is
only transiently present in early endosomes (EEA-1)
at 24 h, and not detected in late endosomes/lyso-
somes (LAMP-1), or the endoplasmic reticulum
(KDEL). Some colocalization was observed with
ERGIC-53 (ER-Golgi intermediate complex), a com-
partment which has been implicated in cross presen-
tation [30]. However, the AFP expressed initially in
the cytoplasm from the AdV construct colocalizes
extensively with Golgi (golgin-97) and trans-Golgi
AB
Fig. 1 Phenotype of AdV-transduced DC. a and (b) Immature DC (iDC) from healthy donors (n = 3) were left untreated, matured with LPS/IFN-γ
(mDC), or transduced with AdVhAFP, and then cultured in DC media for 24, 48, or 72 hr. Cells were stained for (a) antigen presentation and
costimulatory markers and (b) endocytic receptors, and analyzed by flow cytometry. Mean fluorescence intensity (MFI) is reported as
the mean ± SD
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of secreted proteins through the Golgi apparatus for
subsequent release [31].
Unlike native AFP, adenovirally-encoded eGFP-AFP is
retained in the cytoplasm of DC
Native human AFP expressed by adenovirus (AdVhAFP) is
secreted by cells due to a 19 amino acid secretion signal se-
quence at the N-terminus of AFP [32]. An alternativeconstruct was created in which eGFP was fused to the N-
terminus of AFP. Because of the proximity of eGFP to the
N-terminus, this alteration masked the signal sequence and
resulted in eGFP-AFP accumulation in the cytoplasm of
DC. Indeed, while the adenovirally-expressed native AFP
localizes primarily to the perinuclear space (Fig. 3a, left
panel), the adenovirally-expressed eGFP-AFP fusion protein
is detected throughout the cytoplasm (Fig. 3a, middle
panel). DC were also transduced with AdVTyrosinase,
EEA-1
LAMP-1
ERGIC-53
golgin-97
TGN46
24hr 48hr 72hr
KDEL
actin
Fig. 2 Intracellular trafficking of adenovirally-expressed AFP. DC were transduced with AdVhAFP at MOI 2000 for 3 hr, and then cultured in DC
media for 24, 48, or 72 hr. Cells were then fixed and stained for AFP (green), actin, EEA-1 (early endosomes), LAMP-1 (late endosomes/lysosomes),
KDEL (endoplasmic reticulum/ER), ERGIC-53 (ER-Golgi intermediate complex), golgin-97 (Golgi), and TGN46 (trans-Golgi network) (all in red), as
described in Materials and Methods. All images are representative of three independent experiments performed and were taken using a
63x objective
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Fig. 3 Adenovirally-expressed AFP, but not eGFP-AFP, is secreted by transduced DC. a DC were transduced with AdVhAFP (left panel), AdVeGFP-
AFP (middle panel), or AdVTyrosinase at MOI 2000 for 3 hr. After 48 hr, cells were fixed and stained for AFP (left and middle panels), actin (left
and right panels), or Tyrosinase (right panel). Antibody staining of AdVeGFP-AFP-transduced cells with an anti-AFP antibody reveals that AFP and
GFP colocalize, as expected. Representative images from three independent experiments are shown. Images were taken using a 63x objective.
b DC from healthy donors (n = 3) were transduced as above and cultured in DC media for 24, 48, or 72 hr. Supernatants were analyzed by AFP
ELISA. Data are reported as the mean ± SD
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sinase (Fig. 3a, right panel) for comparison. As anticipated,
AdV-driven Tyrosinase and eGFP-AFP displayed similar,
cytoplasmically-localized expression patterns.
Clinical laboratory and ELISA assays were employed to
determine the concentration of AFP secreted into the su-
pernatants of DC transduced with AdVhAFP or AdVeGFP-
AFP. While native AFP is secreted at high levels over three
days post-transduction, eGFP-AFP is undetectable in these
supernatants (Fig. 3b), further confirming that the addition
of eGFP on the AFP N-terminus disrupts and inactivates
the secretion signal.
T cell responses in HD and HCC patients are differentially
induced by secreted and cytoplasmically-retained AFP
constructs
We hypothesized that the presence or absence of the
AFP secretion signal would impact the ability of trans-
duced DC to activate AFP-specific T cells. Healthy donor
PBMC were stimulated with autologous DC transducedwith either AdVhAFP or AdVeGFP-AFP, and CD8+ T
cells were analyzed 23 days later for cytokine production
upon recognition of three immunodominant, HLA-A2-
restricted AFP peptides (Fig. 4a). Four of the 8 tested
donors expanded detectable AFP-specific T cells under
these short-term stimulation conditions. CD8+ T cell re-
sponses against AFP137 and AFP158 were superior in the
AdVhAFP group, whereas both AdVhAFP and AdVeGFP-
AFP generated AFP325-specific responses, indicating some
epitope specific presentation differences between the two
constructs. Neither group was statistically significantly su-
perior (global F-test, p = 0.15). We also measured TNF-α
and IL-2 production by AFP-specific CD4+ T cells in
healthy donors. Again, DC transduced with the secreted
AdVhAFP construct generated higher frequency helper re-
sponses than the cytoplasmically-retained AdVeGFP-AFP
construct (Fig. 4b) although statistical significance was not
reached between the groups (TNF p = 0.25, IL-2 p = 0.13).
We next tested the T cell stimulatory activity of these
AdVs in PBMC from AFP-positive HCC patients. Four
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Fig. 4 Ability of AdV-transduced DC to induce AFP-specific T cell responses. a and (b) DC from HLA-A2+ HDs (n = 4) were transduced with AdVhAFP
or AdVeGFP-AFP at MOI 2000 for 3 hr, then co-cultured with autologous PBMC for 12–13 days. a CD8+ T cells were restimulated with autologous DC
(loaded with AFP as in the initial stimulation) for an additional 10d, and then analyzed for AFP-specific intracellular TNF-α production against three
immunodominant HLA-A2-restricted peptides. b CD4+ T cells were collected after the initial stimulation and analyzed for AFP-specific intracellular
cytokine production. (C and D) DC from HLA-A2+ HCC patients (n = 3–4) were transduced with AdVhAFP or AdVeGFP-AFP at MOI 2000 for 3 hr, then
co-cultured with autologous PBMC for 12–13 days. c CD8+ T cells were collected and analyzed for AFP-specific intracellular TNF-α production against
three immunodominant HLA-A2-restricted peptides. d CD4+ T cells were collected and analyzed for AFP-specific intracellular cytokine production. For
each panel, the solid lines represent the mean value. *, P < 0.05
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specific T cells. Unlike what we observed in healthy
donors, DC transduced with the cytoplasmically-retained
AdVeGFP-AFP induced superior or equivalent CD8+ T
cell responses (with some epitope-specific differences)
versus the AdVhAFP group (Fig. 4c). AFP137 differences
approached significance (p = 0.06) and AFP325 differences
were highly significant (p < 0.0001). HCC patient CD4+ T
cells were also efficiently activated by both constructs(Fig. 4d), suggesting that in individuals with prior exposure
to tumor-derived AFP, but not in healthy donors, robust
AFP-specific T cell responses can be induced by both
secreted and cytoplasmically-retained AFP.
AFP protein upregulates maturation markers and
downregulates endocytic receptors on DC
We have recently shown that monocytes cultured with
HCC tumor-derived AFP (tAFP), but not normal cord
Pardee et al. Journal for ImmunoTherapy of Cancer  (2015) 3:32 Page 7 of 16blood-derived AFP (nAFP), fail to fully differentiate
into DC, despite the fact that nAFP and tAFP isoforms
only differ at one carbohydrate group [33]. Here, we
next investigated the effects of nAFP and tAFP on DC
that were first differentiated before being exposed to
AFP. Compared to untreated iDC, nAFP- and tAFP-
treated DC expressed slightly higher levels of several anti-
gen presentation and costimulatory molecules (Fig. 5a).A
B
Fig. 5 Phenotype of AFP-loaded DC. a and (b) Immature DC (iDC) from he
tAFP (10 μg/ml) in DC media for 24, 48, or 72 hr. Cells were stained for (a)
receptors, and analyzed by flow cytometry. Mean fluorescence intensity (MTogether with our previous study, these data under-
score the multifunctional nature of AFP: potently
suppressive in monocytes, yet somewhat stimulatory in
previously differentiated DC. Expression of the endocy-
tic receptors MR and CD36, however, was diminished in
nAFP- and tAFP-treated DC (Fig. 5b), suggesting that
AFP protein negatively regulates the endocytic activity
of DC.althy donors (n = 3) were left untreated or cultured with nAFP and
antigen presentation and costimulatory markers and (b) endocytic
FI) is reported as the mean ± SD
AActin = red
nAFP = green
Nucleus = blue
0 min
30 min
60 min
Chase:
C
Chase: 0 hr 24 hr
EEA-1
LAMP-1
KDEL
golgin-97
4°
37°
nAFP tAFP
B
Fig. 6 Intracellular trafficking of endocytosed AFP. a nAFP and tAFP were Alexa Fluor 488-labeled. Human monocyte-derived DC were co-
cultured with AFP (10 μg/ml) for 1 hr at 4 °C or 37 °C, and analyzed by flow cytometry. b DC were co-cultured with fluorescently-labeled nAFP
for 2 hr, then chased with media alone for the indicated times. Cells were then fixed, stained for actin (described in Materials and Methods), and
analyzed by confocal microscopy. c DC were incubated with fluorescently-labeled nAFP for 2 hr, then chased with media alone for the indicated
times. Cells were then fixed and stained for EEA-1 (early endosomes), LAMP-1 (late endosomes/lysosomes), KDEL (endoplasmic reticulum/ER), and
golgin-97 (Golgi) (all in red). All images are representative of three independent experiments performed and were taken using a 63x objective
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To understand the dynamics of AFP internalization by
DC, we first labeled nAFP and tAFP with Alexa Fluor
488 and verified by flow cytometry that both proteins
were efficiently taken up by DC (Fig. 6a). AFP endocyto-
sis was further examined by fluorescent microscopy.
After a one hour pulse of DC with fluorescently-labeled
nAFP, cells were chased with media alone for 0, 30, and
60 min (Fig. 6b). Immediately following the AFP antigen
pulse, endocytic pockets containing nAFP are observed
throughout the cytoplasm. This was further examined
with live cell imaging which shows that AFP is detect-
able within DC within 30 s (data not shown). By 30 min
post-pulse, nAFP exhibits a perinuclear localization.
Similar trafficking patterns were observed with tAFP
(data not shown). A recent report [30] identified a peri-
nuclear endosomal recycling compartment (ERC) in DC
which contain high levels of MHC class I molecules, andwhich played a role in cross-presentation. We stained our
AFP loaded DC for MHC class I and did not see colocaliza-
tion (not shown), indicating that the peri-nuclear AFP is
not in an MHC-loaded ERC. Colocalization of nAFP in
intracellular compartments was examined after a one hour
pulse and 0 or 24 h chase (Fig. 6c). Immediately following
the pulse, nAFP colocalized with early endosomes (EEA-1),
but not late endosomes/lysosomes (LAMP-1), endoplasmic
reticulum (KDEL), or Golgi (golgin-97). At 24 h post-pulse,
nAFP exhibited extensive colocalization with LAMP-1,
consistent with a classical MHC Class II processing/presen-
tation paradigm. Similar trafficking patterns were observed
with tAFP (data not shown).
DC endocytose AFP primarily via the mannose receptor
Although an AFP cell surface receptor has been partially
characterized biochemically [17], it has not been defini-
tively cloned. Several molecules have been proposed as
AMR:
99.9%
DC-SIGN:
99.4%
SR-A1:
21.6%
LOX-1:
2.1%
CD36:
99.9%
SR-B1:
29.6%
C-type lectin receptors Scavenger receptors
B
C
MR = red
nAFP = green
D
CD36 = red
nAFP = green
Fig. 7 DC endocytose AFP primarily via the mannose receptor. a DC were stained for flow cytometric analysis. Red histogram represents endocytic
receptor staining; black histogram represents isotype control staining. Data from one representative healthy donor (of three total HD tested) is shown.
b DC were pre-treated with inhibitors for 30 min, and co-cultured with fluorescently-labeled nAFP (top panels) or tAFP (bottom panels) for an additional
1 hr. Percent inhibition was calculated based on untreated control cells. Columns, mean of four HD; bars, standard deviation. c and (d) DC were incubated
with fluorescently-labeled nAFP for 2 hr, then fixed and stained for MR (c) or CD36 (d). All images are representative of three independent experiments
performed and were taken using a 63x objective
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ceptor (MR/CD206) and several scavenger receptors
(SR-A1, LOX-1, CD36, SR-B1) [34]. We first examined
DC for expression of these receptors. As depicted in
Fig. 7a, DC express high levels of MR, DC-SIGN, and
CD36. To identify the mechanism(s) of AFP uptake, DC
were pretreated with inhibitors against pinocytosis
(DMA), CLR-mediated endocytosis (mannan), and scav-
enger receptor-mediated endocytosis (polyinosinic acid;
poly I). Cells were then pulsed with fluorescently-labeled
nAFP and tAFP and uptake inhibition calculated
(Fig. 7b). While the blockade of receptor-independentpinocytosis by DMA displayed moderate suppressive
activity, uptake of nAFP and tAFP was substantially
reduced by mannan and poly I, indicating that CLR- and
scavenger receptor-mediated endocytosis accounts for
the majority of AFP protein internalization. AFP intern-
alization by DC was not abrogated by GalNAc, which in-
hibits galactose-specific CLRs (i.e. MGL) (data not
shown). We also targeted individual CLRs and scavenger
receptors using blocking antibodies. Of those tested,
only the MR blocking antibody demonstrated suppres-
sive activity, suggesting that the primary mechanism of
AFP uptake in DC is through MR-mediated endocytosis.
Pardee et al. Journal for ImmunoTherapy of Cancer  (2015) 3:32 Page 10 of 16We further analyzed the role of MR in AFP uptake
using fluorescent microscopy. Immediately after DC
were pulsed with fluorescently-labeled nAFP, endocytic
pockets containing MR and nAFP, together and co-
localized, were observed throughout the cytoplasm of
DC, further supporting the role of MR in AFP endocyto-
sis (Fig. 7c). Similar trafficking patterns and MR co-
localization were observed with tAFP (data not shown).
No colocalization was observed, however, between endo-
cytosed nAFP and the scavenger receptor CD36
(Fig. 7d).
Because HCC cells are also capable of taking up AFP
[35], endocytosis of nAFP and tAFP by the HCC cell line
HepG2 was also assessed. HepG2 cells take up compar-
able levels of both nAFP and tAFP (Additional file 1:
Figure S1A), although to a lesser degree than DC
(Fig. 6a). We also confirmed that AFP is internalized by
HepG2 cells and not simply bound to the cell surface
(Additional file 1: Figure S1B). Unlike DC, HepG2 cells
do not express CLRs, but express high levels of CD36
and moderate levels of LOX-1 and SR-B1 (Additional file
1: Figure S1C). By utilizing the same uptake inhibition
strategy, we demonstrate that AFP uptake occurs pri-
marily through pinocytosis and scavenger receptors, in
contrast to DC (Additional file 1: Figure S1D).
AFP-specific T cell responses induced by protein-loaded
DC occur in both MR-dependent and –independent
manners
Previous studies by our group have shown AFP protein-
loaded immature DC to be inferior to AdVhAFP-
transduced DC at inducing AFP-specific CD4+ and CD8
+ T cell responses [36, 37]. In this study, the AFP
protein-loaded DC were matured with LPS/IFN-γ prior
to T cell stimulation to determine if a more optimized
protein loading procedure would activate strong T cell
responses. We also wanted to assess both glycoforms of
AFP (nAFP and tAFP), as well as the significance of
MR-mediated AFP endocytosis in the activation of T
cells by DC. Healthy donor DC were pulsed with nAFP
or tAFP in the presence or absence of MR blocking anti-
body, matured for an additional 24 h, then co-cultured
with autologous PBMC. Several days later, CD8+ T cells
were analyzed for cytokine production in response to
AFP-derived peptides (Fig. 8a). This allowed us to detect
cross-presentation of the exogenously added protein,
compared to the cytoplasmically delivered virally
encoded AFP tested above (Fig. 4). In general, multi-
epitope CD8+ T cell responses were generated from both
nAFP or tAFP protein, which was not inhibited by MR
blockade, indicating that the glycosylation state and
route of uptake of AFP by DC are not critical parameters
for priming CD8+ T cells of HD. The frequencies of CD8
+ T cells expanded from protein cross-presentation weregenerally similar to that of cytoplasmic antigen in the
matured DC although the exogenous protein loaded DC
activated significantly more AFP325 or AFP158-specific T
cells (p = 0.007). Robust HD CD4+ T cell responses,
however, were almost completely abrogated by MR
blockade in 3 of 4 donors (Fig. 8b), suggesting that MR-
mediated routing of internalized AFP into the MHC
Class II pathway is important for AFP-specific CD4+ T
cell priming. Exogenous protein yielded higher frequen-
cies of CD4+ T cell responses than either virally encoded
form.
Protein-loaded HCC patient DC were next evaluated
for their T cell stimulatory activity. As with healthy do-
nors, MR blockade did not compromise the ability of
these DC to cross-present antigen and induce high fre-
quency CD8+ T cell activation (Fig. 8c). In fact, MR
blockade significantly increased the frequency of AFP158
and AFP325-specific T cells stimulated by nAFP loaded
DC (p = 0.02 and 0.046, respectively). While inhibiting
tAFP stimulation of AFP158-specific CD8
+ T cells (p =
0.0008). Importantly, MR blockade had a negligible ef-
fect on AFP-specific CD4+ T cell activation in HCC pa-
tients (Fig. 8d). This is in contrast to the reduced CD4+
T cell responses with MR blockade in healthy donors.
These data suggest that HCC patients with AFP-
secreting tumors may have been previously primed by
circulating tAFP, and that our in vitro cultures are test-
ing the loaded DC ability to boost these T cells. Indeed,
the frequencies of AFP-specific CD4+ T cells are much
higher (Figs. 4d and 8d) than from healthy donors
(Figs. 4b and 8b). Together with our AdV-delivered anti-
gen results (Fig. 4), these data show that T cells from
AFP-naïve healthy donors and AFP-experienced HCC
patients are differentially activated by alternative strat-
egies and pathways of DC antigen loading.
Conclusions
Numerous cell surface receptors on DC, including MR,
DEC-205, DC-SIGN, and several scavenger receptors,
mediate the endocytosis of exogenous antigens. Internal-
ized antigen is generally shuttled into lysosomes, where
it is subsequently degraded and presented in the context
of MHC Class II molecules. Alternatively, DC are cap-
able of re-routing internalized antigen into the MHC
Class I pathway via several potential mechanisms [38].
This process, known as cross-presentation, is essential
for the development of protective anti-tumor CD8+ T
cell immunity. Importantly, recent evidence suggests
that the divergence of internalized antigen into either
MHC Class I or Class II pathways may be dictated by
the particular cell surface receptor that was responsible
for endocytosis of the antigen. We have recently shown
that AFP, a secreted oncofetal antigen that is over-
expressed by more than half of HCC tumors, is
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Fig. 8 Ability of AFP protein-loaded DC to induce AFP-specific T cell responses. a and (b) DC from HLA-A2+ HDs (n = 4) were cultured with nAFP
or tAFP (at 10 μg/ml for 2 hr) with or without pre-treatment with MR blocking antibody (at 10 μg/ml for 30 min), matured for an additional 24 h,
then co-cultured with autologous PBMC for 12–13 days. a CD8+ T cells were restimulated with autologous DC (loaded with AFP as in the initial
stimulation) for an additional 10d, and then analyzed for AFP-specific intracellular TNF-α production against three immunodominant HLA-A2-
restricted peptides. b CD4+ T cells were collected after the initial stimulation and analyzed for AFP-specific intracellular cytokine production. c and
(d) DC from HLA-A2+ HCC patients (n = 3–4) were cultured with nAFP or tAFP (at 10 μg/ml for 2 hr) with or without pre-treatment with MR blocking
antibody (at 10 μg/ml for 30 min), matured for an additional 24 h, then co-cultured with autologous PBMC for 12–13 days. (C) CD8+ T cells were collected
and analyzed for AFP-specific intracellular TNF-α production against three immunodominant HLA-A2-restricted peptides. (D) CD4+ T cells were collected
and analyzed for AFP-specific intracellular cytokine production. For each panel, the solid lines represent the mean value. *, P < 0.05
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Here, to identify the endocytosis mechanism(s) respon-
sible for AFP internalization and to determine the down-
stream impact on T cell responses, we co-cultured DCwith fluorescently-labeled AFP in the presence or ab-
sence of inhibitors of specific endocytic pathways.
Pretreatment of DC with mannan, an MR inhibitor
that competitively blocks endocytosis of mannose-rich
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ment with polyinosinic acid, a specific inhibitor of
scavenger receptors, blocked between 50-70 % of AFP
internalization. These data are consistent with the ob-
served high levels of MR and the scavenger receptors
SR-A1 and CD36 expressed by the DC. MR is also
known to be expressed on circulating human BDCA1+
DC [39]. Because AFP is also taken up by HCC cells,
where it is thought to regulate apoptosis and steroid
receptor-mediated cell growth, we performed similar
endocytosis blockade experiments using the HCC cell
line HepG2. In contrast to DC, uptake of AFP by
HepG2 cells was mediated by pinocytosis and several
scavenger receptors, including LOX-1 and CD36.
Vaccines, including cancer vaccines, have utilized many
approaches to convey antigen to stimulatory antigen pre-
senting cells. Ex vivo DC loading strategies include tumor
fusion, tumor lysate loading (with a variety of tumor kill-
ing strategies), purified protein loading, antibody conju-
gate targeting, long peptide loading, and MHC-restricted
short peptide epitope pulsing [40]. Each of these ap-
proaches has been used in clinical trials with variable im-
munologic and therapeutic outcomes [41–43]. The role of
the antigen uptake pathway in not generally addressed in
these studies.
The MR has been shown to be highly expressed on
cultured DC and to be a very efficient antigen uptake re-
ceptor [44]. To improve the uptake efficiency of some
antigens, conjugation of mannose groups has been tested
and shown to improve uptake by DC [45]. This CD206
pathway allows DC to accumulate a large amount of a
variety of antigen molecules as well as microbes with
mannosylated glycoproteins very quickly [3], with very
efficient receptor recycling. Depending on the antigen
glycosylation state, as little as 15 min of antigen uptake
can result in maximal T cell activation [44]. Here, we
show that uptake of AFP is extremely efficient, with
intracellular antigen detected immediately after pulsing.
The mature, circulating form of AFP contains approxi-
mately 4 % carbohydrates by weight, including N-acetyl-
glucosamine (1.2 %), mannose (2.2 %), sialic acid (0.9 %)
and small amounts of glucose [46]. Binding of AFP re-
gions to MR were predicted in silico by an algorithm de-
signed by one of us [47], with AFP 485–493 and AFP
492–500 in domain 3 being critical. As we [33] and
others [48–53] have shown, AFP can have immune sup-
pressive effects on DC and we have shown that a signifi-
cant amount of that activity is due to low molecular
mass (LMM) co-purifying molecules bound to AFP that
is internalized with the AFP. Here, we have shown that
MR-mediated uptake of both nAFP and tAFP is very ef-
ficient, allowing for a quick accumulation of AFP protein
in early endosomes, which can be detected in the peri-
nuclear space for at least 72 h. This uptake pathway may,therefore, enhance the ability of the co-purifying mole-
cules (known to include fatty acids, bilirubin and neop-
terin [54, 55]) to be concentrated inside DC. Blockade of
CD206 reduced HD CD4+ T cell responses, suggesting
that scavenger receptor-mediated uptake does not support
efficient antigen routing for MHC class II presentation,
while CD206 mediated routing through early endosomes
is the most efficient route. Unexpectedly, tAFP and nAFP
behave similarly as antigen sources for CD8+ and CD4+ T
cell activation. The only significant difference we detected
was that MR blockade improved CD8+ T cell responses in
HCC patients from nAFP loaded DC. The frequencies of
tAFP-induced T cells was also higher frequency in HCC
patients than for nAFP.
Replication-deficient AdVs are also an established gene
delivery vehicle, capable of transducing both dividing
and non-dividing cells and inducing prolonged transgene
expression (up to 14 days) into transduced cells [56].
Type 5 AdV bind to the cell surface Coxsackie-
adenovirus receptor (CAR) and cell-surface integrins,
leading to clathrin-mediated endocytosis. The virus-
containing macropinosomes are lysed, releasing the
contents into the cytosol [57]. We found that the
adenovirally-delivered cytoplasmic eGFP-AFP was dif-
fusely localized throughout the cell, without any accu-
mulation in the perinuclear regions. The superiority of
the native secreted form of AFP for priming of both
CD4+ and CD8+ T cell responses in HD may relate to
the high level accumulation of antigen over several days
throughout the ERGIC, Golgi and TGN. Our observa-
tions are also similar to those described by Fukasawa et
al., in which recombinant native AFP was routed into
the secretory pathway of various cell lines via the Golgi,
whereas an AFP construct lacking the N-terminal secre-
tion signal was retained in the cytoplasm and failed to
be secreted [58].
We hypothesize that healthy donor T cells have been
exposed to nAFP, taken up via CD206 and SR pathways,
and presented to CD4+ and CD8+ T cells, during fetal
development through birth. This is in contrast to other
types of self antigens, like cytoplasmically expressed pro-
teins from adult tissues like melanocyte lineage antigens.
HCC patients with tAFP-expressing tumors have been
further exposed as adults to circulating tAFP. While we
demonstrate here that both nAFP and tAFP are effi-
ciently endocytosed by DC via CD206 and SRs, we re-
cently demonstrated that tAFP binds to potently
immune suppressive molecules that can significantly im-
pair DC function and T cell stimulatory activity [33].
Hepatocellular carcinoma (HCC), the most common
form of liver cancer, is the second leading cause of cancer-
related death worldwide [59]. Current therapies for ad-
vanced HCC are marginally effective and can exacerbate
underlying liver disease. The ability of immunotherapy to
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therefore makes it an attractive area of investigation, and
there have been a few intriguing trials with improved out-
comes for vaccinated HCC patients [60, 61]. Importantly, a
minority of HCC tumors are spontaneously infiltrated by
lymphocytes [62], and to date, HCC has not been one of
the more responsive tumor types with checkpoint blockade
with anti-CTLA-4 or anti-PD-1 [63]. It may be critical to
first drive a tumor antigen immune response with vaccin-
ation to create a setting for response to other therapies.
Methods
Reagents
Human cord serum nAFP (Cell Sciences; purity >95 %
by SDS-PAGE), and HCC cell line culture-derived tAFP
(Bio-Rad; purity >95 % by SDS-PAGE) were added to
cultures at 10 μg/ml. Alexa Fluor 488-conjugation of
nAFP and tAFP was performed using an Alexa Fluor
488 protein labeling kit (Life Technologies). Overlapping
peptides (20-mer amino acids overlapping by 10) span-
ning the AFP protein were from Mimotopes (>80 %
purity). Lyophilized peptides were reconstituted in
DMSO and pooled. AFP-derived peptides (AFP137–145:
PLFQVPEPV; AFP158–166: FMNKFIYEI; AFP325–334:
GLSPNLNRFL) were purchased from the University of
Pittsburgh Peptide Synthesis Facility. E1- and E3-deleted
adenoviruses encoding human AFP (AdVhAFP) and en-
hanced green fluorescent protein (eGFP)-tagged AFP
(AdVeGFP-AFP) were acquired from BDP/NCI-Fred-
erick and the University of Pittsburgh Vector Core, re-
spectively. AdVTyrosinase was also acquired from the
University of Pittsburgh Vector Core. Viral titers were
tested using the Adeno-X Rapid Titer Kit (Clontech La-
boratories) and multiplicity of infection (MOI) used to
infect DC was based on the values obtained.Cell lines
HepG2 hepatoma (ATCC #HB-8065) and T2 (HLA-A2
+; ATCC #CRL-1992) cell lines were cultured in RPMI
1640 medium, supplemented with 10 % fetal bovine
serum, 1 % penicillin-streptomycin, and 1 % L-glutamine
(all reagents from Life Technologies). Cultures were
maintained in a humidified 37 °C incubator under 5 %
CO2 tension.
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMC) were ob-
tained from 8 healthy donors (HD) and from 6 HCC pa-
tients banked from an AFP peptide-pulsed DC vaccine
clinical trial [22] (UPCI #04-001; UCLA IRB #00-01-026,
IND BB9395; informed consent was obtained from all
patients and donors). Limited patient data are listed in
Additional file 2: Table S1. PBMC were separated fromblood using gradient centrifugation (Ficoll-Paque, GE
Healthcare).
DC preparation
CD14+ monocytes were isolated from PBMC using mag-
netic cell sorting (Miltenyi Biotec) and cultured for 5 days
in 800 IU/ml rGM-CSF (Sargramostim; Genzyme) and
500 IU/ml rIL-4 (eBioscience; purity >98 % by SDS-PAGE).
Where noted, DC were matured with IFN-γ (1000 IU/ml;
PeproTech) and lipopolysaccharide (LPS, 250 ng/ml;
Sigma-Aldrich) for an additional 24 h prior to collection.
DC were transduced with AdVhAFP, AdVeGFP-AFP, or
AdVTyrosinase for 3 hr in serum-free media at MOI 2000.
Flow cytometry
Endocytic receptors were stained using the following
antibodies: CD206/MR (eBioscience), DC-SIGN, CD36
(both from BD Biosciences), SR-A1 (R&D Systems),
LOX-1 (BioLegend), and SR-B1 (Novus Biologicals). DC
and T cell phenotypes were examined using antibodies
against the following markers: HLA-ABC (BioLegend),
CD206, CD40, CD80, CD83, IL-2 (BD Biosciences),
CD4, CD8, TNF-α, IL-2, and HLA-DR (Beckman
Coulter). Data were acquired with an Accuri C6 cyt-
ometer (BD Biosciences) and analyzed using CFlow Plus
software.Uptake inhibition assays
DC or HepG2 cells were pretreated with inhibitors in
serum-free media for 30 min at 37 °C. Without washing,
fluorescently-labeled protein was added at 10 μg/ml for
1 hr at 37 °C. After washing, MFI of internalized protein
was quantitated by flow cytometry. Percent inhibition
was calculated as: [(MFI of untreated cells) – (MFI of
treated cells)]/(MFI of untreated cells) × 100 %. The fol-
lowing blocking antibodies were used: CD206 (clone
15–2; BioLegend), DC-SIGN (clone 120507), SR-A1
(clone 351620), LOX-1 (clone 331212; all from R&D
Systems), CD36 (clone 185-1G2; NeoMarkers), and
SR-B1 (rabbit polyclonal; Novus Biologicals). Dimethy-
lamiloride (DMA; 100 μM), mannan (300 μg/ml), and
polyinosinic acid (Poly I; 50 μg/ml) were purchased
from Sigma.
Confocal immunofluorescence staining and imaging
DC cultured in 8-well chamber slides (Nunc) were fixed
(4 % paraformaldehyde), permeabilized (0.1 % Triton X-
100), and stained with rhodamine phalloidin (Life Tech-
nologies) and DRAQ5 (eBioscience), to label F-actin and
nuclei, respectively. The following primary antibodies
were used for staining cells: AFP (AbD Serotec), CD206
(BioLegend), CD36, Tyrosinase, EEA-1, LAMP-1, KDEL,
ERGIC-53 (all Santa Cruz Biotechnology), golgin-97
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IgG isotype controls (R&D Systems), and anti-Alexa
Fluor 488 (to amplify the fluorescent signal of Alexa
Fluor 488-labeled protein; Life Technologies). The follow-
ing secondary antibodies were used: goat anti-mouse
Alexa Fluor 488 and 555, goat anti-rabbit Alexa Fluor 488
and 555 (all from Cell Signaling Technology), donkey
anti-goat Cy3 (Jackson ImmunoResearch), donkey anti-
mouse Alexa Fluor-488, and donkey anti-rabbit Alexa
Fluor-488 (both Life Technologies). Images were acquired
using a Leica TCS-SL confocal microscope.
Quantification of secreted AFP by ELISA
Secretion of AFP and eGFP-AFP by adenovirus vector-
transfected DCs was quantified using DuoSet ELISA de-
velopment system for human AFP (R&D Systems) per
the manufacturer’s protocol.
T cell stimulation and cytokine production assays
AFP-loaded DC (via AdVhAFP transduction or AFP
protein pulse) from HLA-A2+ HD or HCC patients
were co-cultured with autologous monocyte-depleted
PBMC at a 1:10 ratio (DC: PBMC) in RPMI 1640 plus
10 % human AB serum plus pen/strep/L-G In plus
20 IU/ml IL-2 and 5 ng/ml IL-7. Cultures were supple-
mented with fresh media containing IL-2 and IL-7 every
3–4 days. After 12–13 days, HD CD4+ T cells and HCC
patient CD8+ and CD4+ T cells were analyzed for AFP-
specific cytokine production, while HD CD8+ T cells
were isolated by magnetic bead selection (Miltenyi
Biotec) and restimulated with autologous DC (loaded
with AFP as in the initial stimulation) for an additional
10d, and then analyzed for AFP-specific cytokine pro-
duction. For CD8+ T cell intracellular cytokine staining,
cells were stimulated in the presence of brefeldin A with
T2 cells pre-loaded with one of three immunodominant
AFP-derived peptides (AFP137–145, AFP158–166, and
AFP325–334; all at 10 μg/ml). Six hours later, T cells were
stained for CD8, fixed, permeabilized, and stained for
intracellular TNF-α. For CD4+ T cell intracellular cyto-
kine staining, cells were stimulated in the presence of
brefeldin A with autologous DC pre-loaded with the
AFP peptide pool (at 60 μg/ml). Six hours later, T cells
were stained for CD4, fixed, permeabilized, and stained
for intracellular IL-2 and TNF-α.
Statistical analysis
To determine the statistical significance of differences in
AFP antigen form and uptake pathways, Figs. 4 and 8
were analyzed as follows. Mixed effects ANOVA were fit
to the data, and the distributions of the residuals were
visually checked using Q-Q plots. While some of the
data demonstrated serious departures from the distribu-
tional assumption, these departures were not present inany of the analyses with statistically significant results.
P values < 0.05 are considered significant and noted with
asterisks in the figures.
Additional files
Additional file 1: Figure S1. HepG2 cells endocytose AFP primarily via
pinocytosis and scavenger receptors. (A) nAFP and tAFP were Alexa
Fluor 488-labeled. HepG2 cells were co-cultured with AFP (10 μg/ml)
for 1 hr at 4 °C or 37 °C, and analyzed by flow cytometry. (B) HepG2
cells were co-cultured with fluorescently-labeled nAFP for 2 hr, then
fixed, stained for actin (described in Materials and Methods), and
analyzed by confocal microscopy. (C) HepG2 cells were stained for flow
cytometric analysis. Red histogram represents endocytic receptor
staining; black histogram represents isotype control staining. Data from
one representative experiment (of three total) is shown. (D) HepG2 cells
were pre-treated with inhibitors for 30 min, and co-cultured with
fluorescently-labeled nAFP (left panel) or tAFP (right panel) for an
additional 1 hr. Percent inhibition was calculated based on untreated
control cells. Columns, mean of three independent experiments; bars,
standard deviation.
Additional file 2: Table S1. HCC patient demographics.
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